stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Return on assets
Beam Therapeutics Inc.'s return on assets over the twelve months to 30 September 2026 was −8.40%, down 2.2 percentage points from fiscal 2025 (−6.19%). Over the past ten years it has ranged from −139.8% (fiscal 2018) to −6.19% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −6.19% | 23.20 |
| FY2024 | −29.4% | (19.93) |
| FY2023 | −9.46% | 11.07 |
| FY2022 | −20.5% | 17.96 |
| FY2021 | −38.5% | 25.96 |
| FY2020 | −64.5% | (8.10) |
| FY2019 | −56.4% | 83.45 |
| FY2018 | −139.8% | (128.34) |
| FY2017 | −11.5% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| BEAM Beam Therapeutics Inc. | −8.40% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −18.2% |
| XNCR Xencor, Inc. compare | −20.4% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −27.8% |
| MBX MBX Biosciences, Inc. compare | −31.3% |
| IDYA IDEAYA Biosciences, Inc. compare | −35.0% |
| RCUS Arcus Biosciences, Inc. compare | −50.6% |
| VRDN Viridian Therapeutics, Inc. compare | −56.5% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement